Tuesday, May 13, 2025

BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics

Related stories

BigID Launches AI Privacy Console for Risk Management

BigID, a leading innovator in data security, privacy, compliance,...

Zencoder Unveils Zen Agents: Custom AI Platform & Marketplace

Breakthrough Technology Empowers Development Teams to Create, Share, and...

Press Ganey Names Avanish Mishra, Ph.D., President, Life Sciences

Press Ganey, the leading provider of experience measurement, analytics,...

QuantHealth Launches AI Model for Clinical Life Sciences

The Foundation Model, Soon to be Available on AWS...

Tricentis Boosts Toolchain in RISE with SAP for AI Cloud

New capabilities help secure and streamline the journey to...
spot_imgspot_img

BD, a leading global medical technology company, announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.

As a result of the collaboration, BD aims to deliver a suite of BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits that can be performed on the Hamilton Microlab® NGS STAR™ robotic liquid-handling platform. The combination will automate steps, including pipetting and thermal cycling, to produce DNA samples or “libraries” that are ready for genetic sequencing.

In single-cell multiomics experiments, constructing libraries of fragmented genetic information that can be read by sequencing instruments is an essential first step before next-generation sequencing (NGS) can be performed and insights from cells can be gathered. NGS library preparation is historically a time-intensive process with manual steps that can result in inconsistent results and compromised data quality.

Also Read: PhaseZero Launches Enterprise-grade, Generative AI Capabilities Built for Global Manufacturers and Distributors

“Multiomics-based assays are increasingly used by single cell researchers in the fields of oncology, immunology and other disciplines to help investigate the various layers of information on a single cell and access a deeper view of health and disease, which is why ensuring reproducible results is critical,” said Steve Conly, worldwide president at BD Biosciences. “By integrating Hamilton’s robotic technology into our end-to-end portfolio of single-cell multiomics solutions, BD continues to leverage automation so that more researchers — whether academic, biopharmaceutical, or contract research organization— are empowered to perform larger scale single-cell multiomics studies with confidence.”

Matt Hamilton, Vice CEO at Hamilton added, “Through this collaboration with BD, we aim to deliver a complete solution for researchers that reduces the potential for biases and enables greater throughput so that labs can achieve their results with greater reliability. As more researchers adopt the rapidly evolving and important approach of single-cell multiomics, we believe that having automated solutions for high-throughput experiments will serve to accelerate their potentially life-changing discoveries.”

SOURCE: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img